Drug Discovery World

JUNE 27, 2023

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. We are thrilled to continue this collaboration as part of our mission to advance impactful agents into the clinic.”

In-Vivo 52

In-Vivo In-Vitro Engineer Protein 52

Drug Discovery World

APRIL 5, 2023

The CBC is the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR), a federal national laboratory sponsored by the NCI, part of the National Institutes of Health, and currently operated by Leidos Biomedical Research.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

FEBRUARY 22, 2024

With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

Drug Discovery World

JANUARY 12, 2023

Organoids are 3D tissue models consisting of multiple cell types that could bridge the gap between traditional 2D in vitro cultures and the actual in vivo tissue of the body. Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Drug Discovery World

OCTOBER 20, 2022

Aqemia’s ‘innovation engine’, the Launchpad, has proven successful in several disclosed and undisclosed collaborations worth up to millions of euros with pharmaceutical companies such as Sanofi, Janssen and Servier.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

JUNE 30, 2023

Select mature stem cell lines can then be used in small-scale in vitro assays, and proven biochemical and phenotypic screens supporting target validation and deconvolution studies. Through the use of human induced pluripotent stem cells (iPSCs) derived cells, we can improve translation and reduce risk of clinical failure.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

FEBRUARY 15, 2023

Sophisticated and continually evolving preclinical IO models (in vivo and in vitro) are particularly helpful in defining translational therapeutic strategies and understanding the efficacy of combination immunotherapies and refractory cancers, and in the identification of novel prognostic biomarkers.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

FEBRUARY 1, 2024

From this enriched selection, promising candidates are identified only after each antibody is characterised both in vitro and in vivo. Time can mean more than money when you’re studying a deadly pathogen. When all is said and done, this process may take months or years to complete.

Antibody 64

Antibody Gene Protein Manufacturing 64

Drug Discovery World

JULY 22, 2022

The company recently implemented CDD Vault registration system and ELN as its central repository for storing, characterizing and managing its libraries, structure activity relationship (SAR) data, and in vitro and other experimental and screening assay data. .

Drugs 98

Drugs In-Vitro In-Vivo Clinical Trials 98

The Pharma Data

JANUARY 4, 2021

The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections. Within the collaboration, ViGeneron will optimize and validate in vitro therapeutic candidates for an undisclosed target to treat inherited eye disease.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

JUNE 17, 2022

“The broadly neutralizing antibodies we described were more efficient in vitro than many anti–SARS-CoV-2 monoclonals previously approved by the FDA for treatment or prevention. A modified version of the Cv2.1169 antibody was also effective at treating SARS-CoV-2 infection in mice and hamsters.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 108

Medicine In-Vivo In-Vitro Development 108

Drug Discovery World

JULY 22, 2022

In vivo models, particularly HIS models, allow preliminary investigation of cell-based therapeutic strategies—often in combination with other therapeutic modalities—to overcome the limitations and challenges of T cell-based immuno-oncology treatments and identify effective options for clinical investigation. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

NOVEMBER 16, 2022

Think of a cell culture, where scientists can observe the growth of a cell in the body in an in-vitro setting, and gain an understanding of how they react to different drug compounds. Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Antibody 52

Antibody Licensing Licensing Development 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

Drug Discovery World

APRIL 3, 2023

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. Optimer binders are engineered to overcome these problems. To what do you attribute your success?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

MAY 10, 2023

Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. billion and take over 10 years.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

Pharmaceutical Technology

APRIL 25, 2023

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

Drug Discovery World

OCTOBER 17, 2022

Data lakes served this same purpose, but while the idea was good, the results of search engines were often disappointing. It takes the right skill set, good information, and the ability to change course as needed. The ability to do this is essential at each of the three steps in the drug discovery process – create, test, and choose.

Marketing 52

Marketing Scientist Gene Expression Drugs 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. However, this has since changed, and now, transitioning between academia and industry has become more commonplace. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

Pharmaceutical Technology

FEBRUARY 28, 2023

It was engineered with an Fc-silent IgG1 isotype to avoid activation of Fc-receptor-mediated non-specific immune. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials. Topic sponsors are not involved in the creation of editorial content.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130